Administration Case Report With EXPAREL

This case report represents the individual experience of Dr Paul Sethi and is intended to demonstrate his methodology for using EXPAREL in a specific orthopedic procedure.

Pacira Pharmaceuticals, Inc. recognizes that there are alternative methodologies for administering local anesthetics, as well as individual patient considerations when selecting the dose for a specific procedure.

EXPAREL is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

<table>
<thead>
<tr>
<th>CASE INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician Name</td>
</tr>
<tr>
<td>Affiliation</td>
</tr>
<tr>
<td>Surgical Case Performed</td>
</tr>
<tr>
<td>Inpatient or Outpatient Procedure</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PATIENT CHARACTERISTICS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
</tr>
<tr>
<td>Age</td>
</tr>
<tr>
<td>Patient History and Characteristics</td>
</tr>
<tr>
<td>Pathology</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PROCEDURAL DETAILS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incision Size</td>
</tr>
<tr>
<td>Preoperative Analgesics Used</td>
</tr>
<tr>
<td>Intraoperative Analgesics Used</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dose of EXPAREL and Total Volume Used</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXPAREL (266 mg) + Normal Saline</td>
</tr>
<tr>
<td>= 60 mL</td>
</tr>
</tbody>
</table>

The recommended dose of EXPAREL is based on the size of the surgical site, the volume required to cover the area, and individual patient factors that may impact the safety of an amide local anesthetic. The maximum dose of EXPAREL should not exceed 266 mg.

EXPAREL can be administered unexpanded (20 mL) or expanded to increase volume up to a total of 300 mL (final concentration of 0.89 mg/mL [ie, 1:14 dilution by volume]) with normal (0.9%) saline or lactated Ringer’s solution.

Bupivacaine HCl may be administered immediately before EXPAREL or admixed in the same syringe, as long as the ratio of the milligram dose of bupivacaine HCl to EXPAREL does not exceed 1:2. Admixing may impact the pharmacokinetic and/or physiochemical properties of EXPAREL, and this effect is concentration dependent. The toxic effects of these drugs are additive and their administration should be used with caution, including monitoring for neurological and cardiovascular effects related to local anesthetic systemic toxicity. Other than with bupivacaine HCl, EXPAREL should not be admixed with other drugs prior to administration.

Please see Important Safety Information on the last page and refer to the accompanying full Prescribing Information for complete Dosage and Administration information before using EXPAREL.
ASSESS THE SIZE OF THE SURGICAL SITE AND DEPTH OF TISSUE, THEN PREPARED INJECTION MATERIALS ACCORDINGLY

In this procedure, Dr. Sethi determined a total volume of approximately 60 mL would be needed to create a field block at the surgical site. He expanded 20 mL of EXPAREL® (bupivacaine liposome injectable suspension) with 40 mL of normal saline. No additional bupivacaine HCl was added to the EXPAREL mixture because the patient received an interscalene nerve block with bupivacaine HCl.

20 to 30 mL of 0.5% bupivacaine HCl may be added to the EXPAREL mixture if the patient is not receiving an interscalene nerve block.

DIVIDE INJECTATE INTO SYRINGES WITH NEEDLE SIZES APPROPRIATE FOR INFILTRATION (20- TO 25-GAUGE) AND PLANNED WHICH AREAS TO INFILTRATE WITH EACH INJECTION

For this procedure, Dr. Sethi divided the injectate into three 20-mL syringes with 20-gauge spinal needles.

He then marked off the surgical site as follows:

- Made standard marking of acromion, scapular spine, and clavicle
- Marked a spot 2 cm medial to the medial acromion in the Neviaser portal area, labeled “Point A”
- Drew a line from Point A over the posterior portal, ending at the patient’s axilla, and named that spot “Point B”
- Drew a line from Point B to the long axis of the humerus carried anteriorly. Line should be perpendicular to the line drawn between Points A and B
- Drew a line from Point A lateral to the coracoid process. Line should be perpendicular to the line drawn between Points A and B
- Marked where lines from Point A and Point B intersected, and labeled it “Point C”

After these lines were drawn, Dr. Sethi planned to infiltrate as follows:

**PRIOR TO INCISION**
- Syringe #1: Point A to Point B
- Syringe #2: Point B to Point C
- Syringe #3: Point C to Point A

**GRAPHIC**

Syringe #1:
Inserted syringe 10° anteriorly at Point A until the tip of needle encountered the bony floor of the scapula. After aspirating to ensure needle was not intravascular, Dr. Sethi injected 10 mL of expanded EXPAREL. He then continued to inject 1 to 1.5 mL every 1 to 1.5 cm along the line between Points A and B.

You will likely run out of injectate in Syringe #2 before reaching Point C. Use Syringe #3 to complete infiltration to Point C.

**FIGURE 1.** Point A to Point B

**FIGURE 2.** Point B to Point C

**FIGURE 3.** Point C to Point A

20 to 30 mL of 0.5% bupivacaine HCl may be added to the EXPAREL mixture if the patient is not receiving an interscalene nerve block.

**INfiltration Notes (cont)**

Syringe #1:
Inserted needle at Point B down to the bone and injected 7.5 to 10 mL of expanded EXPAREL. Then Dr. Sethi continued to inject 1 to 1.5 mL every 1 to 1.5 cm along the line between Points B and C.

You will likely run out of injectate in Syringe #2 before reaching Point C. Use Syringe #3 to complete infiltration to Point C.

**FIGURE 1.** Point A to Point B

**FIGURE 2.** Point B to Point C

**FIGURE 3.** Point C to Point A

20 to 30 mL of 0.5% bupivacaine HCl may be added to the EXPAREL mixture if the patient is not receiving an interscalene nerve block.

**INfiltration Notes (cont)**

Syringe #2:
Inserted needle at Point B down to the bone and injected 7.5 to 10 mL of expanded EXPAREL. Then Dr. Sethi continued to inject 1 to 1.5 mL every 1 to 1.5 cm along the line between Points B and C.

You will likely run out of injectate in Syringe #2 before reaching Point C. Use Syringe #3 to complete infiltration to Point C.

**FIGURE 1.** Point A to Point B

**FIGURE 2.** Point B to Point C

**FIGURE 3.** Point C to Point A

20 to 30 mL of 0.5% bupivacaine HCl may be added to the EXPAREL mixture if the patient is not receiving an interscalene nerve block.

**INfiltration Notes (cont)**

Syringe #3:
Infiltrated 1 to 1.5 mL of expanded EXPAREL every 1 to 1.5 cm until Point C was reached. Then Dr. Sethi continued to infiltrate along the line between Points C and A until all remaining injectate was used.

Injections from Points C to A must be lateral to the coracoid and should not be carried to the bone.

**FIGURE 1.** Point A to Point B

**FIGURE 2.** Point B to Point C

**FIGURE 3.** Point C to Point A

Please see Important Safety Information on the last page and refer to the accompanying full Prescribing Information for complete Dosage and Administration information before using EXPAREL.
PROPER TECHNIQUE IS CRUCIAL FOR ANALGESIC COVERAGE

Dr Sethi infiltrated EXPAREL® (bupivacaine liposome injectable suspension) into all tissue layers using a moving needle technique. With a moving needle technique, the injections were spread in a fan-like pattern and occurred as the needle was both inserted and withdrawn to maximize the coverage area. This technique was systematically and meticulously repeated at each injection site, with overlapping diffusion of EXPAREL to ensure there were no gaps in analgesic coverage.

Watch Dr Sethi infiltrate with EXPAREL at www.EXPAREL.com

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death.

Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Disclosure: Dr Sethi is a paid consultant for Pacira Pharmaceuticals, Inc.